Get the Stockscreener App
1.26
3.82%
-0.05
Pre-market:
1.27
0.01
+0.79%
Inmune Bio Inc stock is traded at $1.26, with a volume of 537.38K.
It is down -3.82% in the last 24 hours and down -25.88% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$1.31
Open:
$1.3
24h Volume:
537.38K
Relative Volume:
1.33
Market Cap:
$33.50M
Revenue:
$50,000
Net Income/Loss:
$-49.89M
P/E Ratio:
-0.5888
EPS:
-2.1398
Net Cash Flow:
$-31.55M
1W Performance:
-12.50%
1M Performance:
-25.88%
6M Performance:
-47.72%
1Y Performance:
-85.33%
1-Day Range:
$1.2102
$1.3399
1-Week Range:
$1.2102
$1.4754
52-Week Range:
$1.2102
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.26 | 34.83M | 50,000 | -49.89M | -31.55M | -2.1398 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.01 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.04 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
826.25 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.35 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
370.64 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
INmune Bio Advances XPro Toward Registrational Alzheimer’s Study - TipRanks
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar - The Manila Times
INmune Bio Inc. Announces Webinar on XPro1595 Registrational Pathway for Early Alzheimer's Disease Treatment - Quiver Quantitative
Alzheimer’s therapy XPro1595 nears key trial as INmune Bio details Phase 3 path - Stock Titan
Levels Update: Is INmune Bio Inc stock undervalued right nowMarket Sentiment Review & Daily Stock Trend Reports - baoquankhu1.vn
INmune Bio to host webinar on RDEB treatment data - Investing.com Australia
INmune Bio to Present New CORDStrom Phase III Data - TipRanks
INmune Bio to Host Feb. 26 Webinar Presenting MissionEB Phase III CORDStrom Data - TradingView
INmune Bio to host webinar on RDEB treatment data By Investing.com - Investing.com Nigeria
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB - The Manila Times
INmune Bio Inc. to Host Webinar on CORDStrom Treatment for Recessive Dystrophic Epidermolysis Bullosa, Highlighting New Clinical Data and Insights from MissionEB Study - Quiver Quantitative
New trial data on systemic treatment for a painful skin disease - Stock Titan
INMB stock rises pre-market – what did the FDA say about its Alzheimer’s trial? - MSN
Aug Action: What are INmune Bio Incs earnings expectations2025 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits
Is INmune Bio Inc. stock a buy for dividend growthPortfolio Growth Summary & Technical Analysis for Trade Confirmation - mfd.ru
INmune Bio Advances CORDStrom Toward Rare Disease Commercialization - TipRanks
Inmune Bio Inc Advances CORDStrom and XPro1595 Regulatory Pathways - TradingView
Inmune Bio plans to seek approval of RDEB treatment in UK, US, and EU in 2026 - Epidermolysis Bullosa News
Inmune Bio announces FDA alignment on integrated Phase 2B/3 registration pathway for Xpro1595 in early Alzheimer's disease - marketscreener.com
Inmune Bio announces FDA alignment on integrated phase 2B/3 registration pathway for Xpro1595 in early Alzheimer's disease - marketscreener.com
INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? - Asianet Newsable
INmune Bio Gains FDA Alignment On Phase 2b/3 Trial Design For Alzheimer's Drug XPro1595 - Nasdaq
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease - The Manila Times
Will INmune Bio Inc. benefit from geopolitical trends2025 Market Outlook & Daily Growth Stock Investment Tips - mfd.ru
Is INmune Bio Inc. stock a value trapRate Hike & Safe Entry Momentum Tips - mfd.ru
INmune Bio submits pre-submission package for CORDStrom with MHRA - Yahoo Finance
INmune Bio, Inc. (NASDAQ:INMB) Given Average Rating of “Reduce” by Brokerages - Defense World
Inmune Bio Inc Submitted Pre-Submission Package For Cordstrom With Uk's Mhra - TradingView
Inmune Bio Advances Cordstrom™ Towards Uk Marketing Authorization In Rdeb - TradingView
INmune Bio (INMB) Advances with Regulatory Submission for CORDSt - GuruFocus
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB - The Manila Times
Rare 'butterfly skin' disease therapy takes key step toward UK review - Stock Titan
Death Cross: Whats the profit margin of INmune Bio IncJuly 2025 Gainers & Verified Chart Pattern Signals - baoquankhu1.vn
Smart Money: Will INmune Bio Inc benefit from geopolitical trendsJuly 2025 Trends & Consistent Profit Trading Strategies - baoquankhu1.vn
Retail Surge: What is the earnings history of INmune Bio Inc2025 Valuation Update & Fast Gaining Stock Reports - baoquankhu1.vn
Aug Movers: Will INmune Bio Inc benefit from geopolitical trendsInsider Buying & Expert Approved Momentum Ideas - baoquankhu1.vn
INmune Bio: Undervalued Pipeline with 2026 Clinical and Regulatory Catalysts Driving Buy Rating - TipRanks
INmune Bio outlines 2025 progress on Alzheimer’s and RDEB therapies By Investing.com - Investing.com Australia
New Highs: Can ProShares Trust ProShares UltraShort SmallCap600 expand into new marketsDollar Strength & Reliable Intraday Trade Plans - baoquankhu1.vn
INmune Bio outlines 2026 regulatory path in shareholder letter - TipRanks
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - TradingView
INmune Bio (INMB) Reflects on Key Progress and Financial Stabili - GuruFocus
INmune Bio (INMB) Reflects on Key Progress and Financial Stability in 2025 - GuruFocus
INmune Bio outlines 2025 progress on Alzheimer’s and RDEB therapies - Investing.com
INmune Bio, Inc. Provides Investor Update on 2025 Progress and Future Regulatory Plans - Quiver Quantitative
Sell Signal: Will Reading International Inc benefit from geopolitical trends2025 Trading Recap & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Aug Rallies: What is the earnings history of INmune Bio IncMarket Performance Report & Daily Technical Forecast Reports - baoquankhu1.vn
Is INmune Bio Inc. trading at a discountDay Trade & Reliable Price Breakout Alerts - bollywoodhelpline.com
Take Profit: Is Varex Imaging Corporation still a buy after recent gains - baoquankhu1.vn
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial - MSN
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):